Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone / 부인종양
Nazli TOPFEDAISI-OZKAN; Mehmet-Mutlu MEYDANLI; Mustafa-Erkan SARI; Fuat DEMIRKIRAN; Ilker KAHRAMANOGLU; Tugan BESE; Macit ARVAS; Hanifi ŞAHIN; Ali HABERAL; Husnu CELIK; Gonca COBAN; Tufan OGE; Omer-Tarik YALCIN; Özgür AKBAYIR; Baki ERDEM; Ceyhun NUMANOĞLU; Nejat ÖZGÜL; Gökhan BOYRAZ; Mehmet-Coşkun SALMAN; Kunter YÜCE; Murat DEDE; Mufit-Cemal YENEN; Salih TAŞKIN; Duygu ALTIN; Uğur-Fırat ORTAÇ; Hülya AYDIN-AYIK; Tayup ŞIMŞEK; Tayfun GÜNGÖR; Kemal GÜNGÖRDÜK; Muzaffer SANCI; Ali AYHAN.
Journal of Gynecologic Oncology
; : e65-2017.
Artículo
en Inglés
| WPRIM | ID: wpr-54946
OBJECTIVE:
To determine factors influencing overall survival following recurrence (OSFR) in women with low-risk endometrial cancer (EC) treated with surgery alone.METHODS:
A multicenter, retrospective department database review was performed to identify patients with recurrent “low-risk EC” (patients having less than 50% myometrial invasion [MMI] with grade 1 or 2 endometrioid EC) at 10 gynecologic oncology centers in Turkey. Demographic, clinicopathological, and survival data were collected.RESULTS:
We identified 67 patients who developed recurrence of their EC after initially being diagnosed and treated for low-risk EC. For the entire study cohort, the median time to recurrence (TTR) was 23 months (95% confidence interval [CI]=11.5–34.5; standard error [SE]=5.8) and the median OSFR was 59 months (95% CI=12.7–105.2; SE=23.5). We observed 32 (47.8%) isolated vaginal recurrences, 6 (9%) nodal failures, 19 (28.4%) peritoneal failures, and 10 (14.9%) hematogenous disseminations. Overall, 45 relapses (67.2%) were loco-regional whereas 22 (32.8%) were extrapelvic. According to the Gynecologic Oncology Group (GOG) Trial-99, 7 (10.4%) out of 67 women with recurrent low-risk EC were qualified as high-intermediate risk (HIR). The 5-year OSFR rate was significantly higher for patients with TTR ≥36 months compared to those with TTR <36 months (74.3% compared to 33%, p=0.001). On multivariate analysis for OSFR, TTR <36 months (hazard ratio [HR]=8.46; 95% CI=1.65–43.36; p=0.010) and presence of HIR criteria (HR=4.62; 95% CI=1.69–12.58; p=0.003) were significant predictors.CONCLUSION:
Low-risk EC patients recurring earlier than 36 months and those carrying HIR criteria seem more likely to succumb to their tumors after recurrence.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados